Please assess the completion status of the following clinical trial:

Trial Title: Simvastatin in Waldenstrom's Macroglobulinemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18 years of age or older~* Clinicopathological diagnosis of Waldenstrom's macroglobulinemia~* Measurable disease~* Slowly progressing disease not requiring therapy for at least 3-6 months and who do not meet consensus panel criteria for initiation of therapy~* ECOG Performance status of 0 or 1~* Adequate organ function as defined in the protocol~* Patients should agree to avoid grapefruit juice which is a major inhibitor of CYP 3A4~Exclusion Criteria:~* Patients who have had chemotherapy or radiotherapy within 4 weeks prior to entering the study, or those who have not recovered from adverse events due to agents administered more than four weeks earlier~* Patients who have had rituximab within 3 months prior to entering the study~* Patients who have taken any Statin in the past~* Patients who take cyclosporin, danazol, or gemfibrozil will be excluded~* Prior history of rhabdomyolysis~* Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with the study requirements~* Pregnant or breastfeeding women~* HIV-positive~* Patients who take verapamil will be excluded~* Patients with active or history of liver disease~* Patients who consume more than three alcoholic beverages per day

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Simvastatin (Type: EXPERIMENTAL): Simvastatin at 20 mg daily for the first week, then dose escalated weekly by 20 mg a day to a maximum of 80 mg daily by week 4. Patients were maintained on therapy until progression.

Based on this trial design, predict the completion outcome and termination type (if applicable).